Lives unaffected by cystic fibrosis

13 August 2021

Conquer CF (Respiratory) Innovation Grant

Cystic Fibrosis Australia (CFA) is pleased to announce the second Conquer Cystic Fibrosis Innovation Grant for 2021. This Respiratory Grant is looking for ‘big thinkers’ with great innovative ideas who will make a difference through research to the CF community.  It is open to post-doctoral researchers, scientists, clinicians, medical practitioners, nurses and allied health currently working in the area of cystic fibrosis (CF) or proposing to work in CF research in the Respiratory field.  Respiratory is defined here to include any part of the respiratory tract, as well as directly related issues such as sinus and asthma, and lungs.  The researchers will have completed their studies in CF or a related area within the past five years.

The Conquer CF Innovation Grant will allow a CF researcher to explore novel concepts at the initial feasibility stage. Innovative applications relating to Respiratory aspects of CF are encouraged, even those lacking pilot data. The grant aims to allow the researcher to generate sufficient data within the one-year grant period to be in a position to apply for additional support from an appropriate funding body to continue the research.

The recipients of the Conquer CF Innovation Grant are required to provide progress reports on their research to CFA every six months. In addition, and where appropriate, the recipient will be asked to make a presentation at a CFA conference (held every two years) in Australia.

The maximum amount awarded for the Conquer CF Innovation Grant will be $50,000. The actual amount provided will be subject to approval of the applicant’s budget.

Applications can be made through the CFA website and must be received no later than 5.00 pm AEST Monday, 13th September 2021.

Conquer Cystic Fibrosis is a volunteer-run charity founded and driven by West Australian parents of children with the disease. Its primary aim is to fund CF research which will decrease suffering and increase the life span of people with CF.